Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise
Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.
This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.
Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.
This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.
Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.
This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.
Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.
This is a negative factor that could pressure the stock, providing a balanced view of risks.